Skip to content

Price / sales at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
1.3×-0.1×
Viatris logo
ViatrisVTRS
1.1×+0.3×
PTH
Pelthos Therapeutics Inc.PTHS
2.5×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
1.7×+0.1×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.5×-5.5×
Opko Health logo
Opko HealthOPK
1.5×-0.1×

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

Based on the most recent quarter.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's price / sales?
Scilex Holding Company (SCLX) reported price / sales of 1.4× in Q1 2026.
How has Scilex Holding Company's price / sales changed year-over-year?
Scilex Holding Company's price / sales increased by 54.0% year-over-year, from 0.9× to 1.4×.
What is the long-term trend for Scilex Holding Company's price / sales?
Over 4 years (2021 to 2025), Scilex Holding Company's price / sales has grown at a -50.0% compound annual growth rate (CAGR), from 45.2× to 2.8×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.